| James C Robinson, LPCC | |
|
408 Harrisburg Hill Rd, Alexandria, KY 41001-7692 | |
| (513) 518-0356 | |
| Not Available |
| Full Name | James C Robinson |
|---|---|
| Gender | Male |
| Speciality | Counselor |
| Location | 408 Harrisburg Hill Rd, Alexandria, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205495819 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | 0210 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James C Robinson, LPCC 408 Harrisburg Hill Rd, Alexandria, KY 41001-7692 Ph: (513) 518-0356 | James C Robinson, LPCC 408 Harrisburg Hill Rd, Alexandria, KY 41001-7692 Ph: (513) 518-0356 |
News Archive
Researchers in the United Kingdom have determined that azithromycin, a broad-spectrum antibiotic that also has anti-inflammatory properties, can be an effective treatment option for patients suffering from bronchiolitis obliterans syndrome (BOS), a life-threatening complication that occurs in the majority of patients following lung transplantation.
Astragaloside IV, the main component of the traditional Chinese medicine astragalus membra-naceus, has been shown to inhibit inflammation, oxidation, and apoptosis, and exerts immu-noregulatory effects. Xiaohong Zhang and colleagues from School of Pharmacutical Sciences, Jilin University investigated whether astragaloside IV could promote the repair of injured sciatic nerve.
Women are significantly less likely than men to be awarded grants and New Investigator personnel awards from the Canadian Institutes of Health Research, according to a new study published this week in PLOS Medicine by Karen Burns of the University of Toronto, Canada, and colleagues.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
For millions of Americans with Type-2 diabetes and inject insulin to control diabetes (with onset typically in adulthood) the associated risk of cancer is of increasing concern. Studies have demonstrated that obesity and excess insulin - whether naturally produced by the body or injected in synthetic form - are associated with an increased incidence of some common cancers.
› Verified 9 days ago
Christina Howard, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 8333 Alexandria Pike, Alexandria, KY 41001 Phone: 859-462-1685 | |
Tammy Siry, LPCC-S Counselor Medicare: Not Enrolled in Medicare Practice Location: 23 Sheridan Dr, Alexandria, KY 41001 Phone: 859-620-8209 |